From: Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
Histopathological parameters of the primary tumor | No (%) |
---|---|
Breslow thickness | |
<1 mm | 34 (32.7) |
1.01-2.00 mm | 20 (19.2) |
2.01-4.00 mm | 27 (26.0) |
>4 mm | 23 (22.1) |
Clark level | |
I | 0 (0.0) |
II | 18 (17.3) |
III | 49 (47.1) |
IV | 26 (25.0) |
V | 11 (10.6) |
Histologic type | |
Superficial spreading melanoma (SSM) | 68 (65.4) |
Nodular malignant melanoma (NMM) | 32 (30.8) |
Acral-lentiginous melanoma (ALM) | 4 (3.8) |
Mitotic rate | |
0 | 45 (43.3) |
1-2 | 26 (25.0) |
≥3 | 33 (31.7) |
Ulceration | |
No | 55 (52.9) |
Yes | 49 (47.1) |
Lymphangioinvasion | |
No | 74 (71.2) |
Yes | 30 (28.8) |
Growth phase | |
Radial | 3 (2.9) |
Vertical | 101 (97.1) |
Tumor-infiltrating lymphocytes (TILs) | |
No | 18 (17.3) |
Nonbrisk | 34 (32.7) |
Brisk | 52 (50) |
Microsatellitosis | |
No | 98 (94.2) |
Yes | 6 (5.8) |
Tumor regression | |
No | 96 (92.3) |
Yes | 8 (7.7) |